Abstract:ABSTRACT Guanylate-binding protein (GBP) 5 is an interferon-inducible cellular factor with broad anti-viral activity. Recently, GBP5 has been shown to antagonize the glycoproteins of a number of enveloped viruses, in part by disrupting the host enzyme furin. Here we show that GBP5 strongly impairs the infectivity of virus particles bearing not only viral glycoproteins that depend on furin cleavage for infectivity—the envelope (Env) glycoproteins of HIV-1 and murine leukemia virus and the spike (S) glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)—but also viral glycoproteins that do not depend on furin cleavage: vesicular stomatitis virus glycoprotein and SARS-CoV S. We observe that GBP5 disrupts proper N -linked protein glycosylation and reduces the incorporation of viral glycoproteins into virus particles. The glycosylation of the cellular protein CD4 is also altered by GBP5 expression. Flow cytometry analysis shows that GBP5 expression reduces the cell-surface levels of HIV-1 Env and the S glycoproteins of SARS-CoV and SARS-CoV-2. Our data demonstrate that, under the experimental conditions used, inhibition of furin-mediated glycoprotein cleavage is not the primary anti-viral mechanism of action of GBP5. Rather, the antagonism appears to be related to impaired trafficking of glycoproteins to the plasma membrane. These results provide novel insights into the broad antagonism of viral glycoprotein function by the cellular host innate immune response. IMPORTANCE The surface of enveloped viruses contains viral envelope glycoproteins, an important structural component facilitating virus attachment and entry while also acting as targets for the host adaptive immune system. In this study, we show that expression of GBP5 in virus-producer cells alters the glycosylation, cell-surface expression, and virion incorporation of viral glycoproteins across several virus families. This research provides novel insights into the broad impact of the host cell anti-viral factor GBP5 on protein glycosylation and trafficking.

Guanylate-Binding Protein 1 Inhibits Inflammatory Factors Produced by H5N1 Virus Through Its GTPase Activity

The Innate Immunity of Guinea Pigs Against Highly Pathogenic Avian Influenza Virus Infection

Inducible GBP5 Mediates the Antiviral Response via Interferon-Related Pathways during Influenza A Virus Infection

Guanylate-binding Protein 1 Restricts Avian Coronavirus Infectious Bronchitis Virus-Infected HD11 Cells

Guanylate‐binding protein 1 inhibits Hantaan virus infection by restricting virus entry

Guanylate-binding protein 5 antagonizes viral glycoproteins independently of furin processing

Guanylate-binding Protein 1 Participates in Cellular Antiviral Response to Dengue Virus

The pseudogene GBP1P1 suppresses influenza A virus replication by acting as a protein decoy for DHX9

The IFN‐inducible GTPase IRGB10 Regulates Viral Replication and Inflammasome Activation During Influenza A Virus Infection in Mice

Guanylate-binding Protein 1 Inhibits Nuclear Delivery of Pseudorabies Virus by Disrupting Structure of Actin Filaments

[Recent Progress in Interferon Induced Protein GBP1 Research].

Characterization of porcine P58IPK gene and its up-regulation after H1N1 or H3N2 influenza virus infection

Immunomodulatory and antiviral effects of Lycium barbarum glycopeptide on influenza a virus infection

Effects of the PA-X and PB1-F2 Proteins on the Virulence of the 2009 Pandemic H1N1 Influenza A Virus in Mice.

Interferon-γ-induced GBP1 is an inhibitor of human papillomavirus 18

Porcine reproductive and respiratory syndrome virus non-structural protein 4 cleaves guanylate-binding protein 1 via its cysteine proteinase activity to antagonize GBP1 antiviral effect

Antiviral mechanisms of guanylate-binding protein 5: versatile inhibition of multiple viral glycoproteins

Galectin-1 Ameliorates Influenza A H1N1pdm09 Virus-Induced Acute Lung Injury.

GGCX promotes Eurasian avian-like H1N1 swine influenza virus adaption to interspecies receptor binding

Guanylate-Binding Protein 1 (GBP1) Enhances IFN-α Mediated Antiviral Activity against Hepatitis B Virus Infection